Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Merli

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
World Journal of Clinical Oncology|July 21, 2011
Rituximab maintenance in follicular lymphoma patientsLuca Arcaini, Michele Merli
American Journal of Hematology|October 18, 2019
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!Michele Merli, Francesco Passamonti
Hematology. American Society of Hematology. Education Program|December 9, 2022
Management of marginal zone lymphomasMichele Merli, Luca Arcaini
British Journal of Haematology|August 18, 2023
Deciphering molecular complexity of HCV-associated lymphoproliferationMichele Merli, Francesco Passamonti, Luca Arcaini
Haematologica|February 5, 2008
Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemiaCarlo Castagnola, Chiara Elena, Michele Merli
Leukemia & Lymphoma|September 29, 2021
The double significance of idelalisib immune-related toxicityMichele Merli, Francesco Passamonti, Luca Arcaini
World Journal of Gastroenterology|October 28, 2016
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphomaMichele Merli, Giuseppe Carli, Luca Arcaini, et al.
Expert Opinion on Pharmacotherapy|February 1, 2017
Antiviral therapies for managing viral hepatitis in lymphoma patientsMichele Merli, Sara Rattotti, Manuel Gotti, et al.
American Journal of Hematology|May 21, 2013
Looking for familial nodular lymphocyte-predominant Hodgkin lymphomaMichele Merli, Margherita Maffioli, Andrea Ferrario, et al.
Hematology/Oncology Clinics of North America|September 27, 2012
Clinical predictors of outcome in MPNFrancesco Passamonti, Margherita Maffioli, Michele Merli, et al.
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
World Journal of Clinical Oncology|July 21, 2011
Rituximab maintenance in follicular lymphoma patientsLuca Arcaini, Michele Merli
American Journal of Hematology|October 18, 2019
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!Michele Merli, Francesco Passamonti
Hematology. American Society of Hematology. Education Program|December 9, 2022
Management of marginal zone lymphomasMichele Merli, Luca Arcaini
British Journal of Haematology|August 18, 2023
Deciphering molecular complexity of HCV-associated lymphoproliferationMichele Merli, Francesco Passamonti, Luca Arcaini
Haematologica|February 5, 2008
Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemiaCarlo Castagnola, Chiara Elena, Michele Merli
Leukemia & Lymphoma|September 29, 2021
The double significance of idelalisib immune-related toxicityMichele Merli, Francesco Passamonti, Luca Arcaini
World Journal of Gastroenterology|October 28, 2016
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphomaMichele Merli, Giuseppe Carli, Luca Arcaini, et al.
Expert Opinion on Pharmacotherapy|February 1, 2017
Antiviral therapies for managing viral hepatitis in lymphoma patientsMichele Merli, Sara Rattotti, Manuel Gotti, et al.
American Journal of Hematology|May 21, 2013
Looking for familial nodular lymphocyte-predominant Hodgkin lymphomaMichele Merli, Margherita Maffioli, Andrea Ferrario, et al.
Hematology/Oncology Clinics of North America|September 27, 2012
Clinical predictors of outcome in MPNFrancesco Passamonti, Margherita Maffioli, Michele Merli, et al.
Pageof 12